IceCure Medical shares surge 10.08% premarket after FDA authorizes ProSense® cryoablation for low-risk breast cancer in women aged 70+.

IceCure Medical Ltd. (ICCM) surged 10.08% in premarket trading following the announcement that its ProSense® Cryoablation System received regulatory approval in Switzerland for treating breast, lung, liver, and kidney cancers. This approval expands the system’s commercial potential in Europe, reinforcing the company’s recent momentum from prior milestones, including FDA authorization for breast cancer treatment in women aged 70 and above. The news aligns with IceCure’s strategy to broaden access to its minimally invasive cryoablation technology, potentially driving revenue growth and market share in oncology. Other recent updates, such as a COO promotion and upcoming Q3 earnings, were not material to the premarket rally.